MedTrace Logo

RT-01 Monotherapy and in Combination With Nivolumab in Patients With Advanced Solid Tumors

NCT05122572 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 36

Last updated 2022-01-20

No results posted yet for this study

Summary

This is a single-arm, open-lable study to determine the safety, tolerability and preliminary efficacy of oncolytic virus injection (RT-01) combined with or without immune checkpoint inhibitors (Nivolumab) in the treatment of patients with advanced solid tumors.

Conditions

  • Advanced Solid Tumor

Interventions

BIOLOGICAL

Oncolytic Virus Injection (RT-01）

Intravenous injection of RT-01 with or without Nivolumab

Sponsors & Collaborators

  • Wuxi People's Hospital

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-11-01
Primary Completion
2022-06-01
Completion
2023-06-01

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05122572 on ClinicalTrials.gov